Efficacy and Safety of Rozanolixizumab to Treat Myasthenia Gravis

Mechanism of Action of Rozanolixizumab to Treat Myasthenia GravisПодробнее

Research Webinar: Update on RozanolixizumabПодробнее

Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravisПодробнее

Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMMLПодробнее

Updated efficacy and safety of anti-BCMA CAR-T for the treatment of R/R AL amyloidosisПодробнее

UCB Announces Positive Phase 3 Results for Zilucoplan in Generalized Myasthenia GravisПодробнее

Updates on Rozanolixizumab and Zilucoplan To Treat Myasthenia GravisПодробнее

UCB Announces Phase 3 Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis (gПодробнее

Efficacy and Safety of Weekly Subcutaneous Efgartigimod for Myasthenia GravisПодробнее

Research Webinar Series: New Treatment for Generalized Myasthenia GravisПодробнее

ADAPT analysis: efgartigimod for generalized myasthenia gravisПодробнее

ASH Highlights: Efgartigimod Safe and Effective in Treating Immune Thrombocytopenia (ITP)Подробнее

Updates on Treatment for MGПодробнее

Clinical Trial: Rozanolixizumab for MOG Antibody-associated Disease (NCT05063162)Подробнее

Two Different Approaches in the Treatment of gMG.Подробнее

Research Updates in Myasthenia GravisПодробнее

Myasthenia Gravis: An Evolving Treatment Strategy by Dr. Satheesh Kumar Bokka, PGY-4 Chief ResidentПодробнее

#LetsTalkNMD Webinar Series - Myasthenia Gravis & YouПодробнее

Phase 3 CHAMPION Clinical Trial For Myasthenia GravisПодробнее